MAP2K7 and Miyoshi myopathy: Of the 24 patients with at least one FDG-avid focal lesion on PET imaging before starting trametinib, 15 experienced an >50% reduction in the number of focal lesions, with 10 achieving a PET complete response, suggesting that MEK inhibition has activity in MM, although this needs to be studied further in extramedullary sites of disease [139].